Myonex, a leading provider of comprehensive clinical trial supply solutions, has finalized the acquisition of CREAPHARM’s pharmaceutical services. This move integrates CREAPHARM’s clinical packaging and distribution services, commercial packaging operations, and bioservices under the Myonex brand, enhancing its capabilities for both clinical and commercial pharmaceutical and biotech clients, including those managing advanced therapies. James Lovett, CEO of Myonex, expressed enthusiasm for the acquisition and its expansion of services, affirming their readiness to meet dynamic client needs with agility and reliability. The acquisition also brings new executive talent, with Eric Placet, CREAPHARM’s founder and former CEO, joining Myonex’s board, and Carla Da Costa stepping in as COO. Myonex is poised for growth, backed by the expertise of legal advisers McDermott Will & Emery in France, Troutman Pepper in the US, and Crosstree Capital Partners as financial advisers. CREAPHARM was advised by ARST Avocats and Nomodos in France, with Nelson Mullins and Rothschild & Co. in the US. Myonex operates nine sites across the US, Germany, and the UK, partnering with pharmaceutical and biotech companies, contract research organizations (CROs), and clinical trial service providers.

Pharmaceutical & Biotech, Clinical Trial Supply & Management, Mergers & Acquisitions,United States, France